Lexicon Pharmaceuticals (NASDAQ:LXRX)
continues to languish (down 25% over the past year, but up almost 17%
over the last six months) amid a hot biotech market as investors are
paying very little attention to the company's carcinoid drug and largely
writing off the dual SGLT-1/2 inhibitor sotagliflozin. That may yet
prove to be a premature decision, though, as the company is moving into
its Phase III program in Type 1 diabetes (whereas competing SGLT-2 drugs
are approved for Type 2 diabetes, but used off-label in Type 1) and may
have an emergent opportunity to stand out with its safety profile.
Continue here:
Can Lexicon Pharmaceuticals Make Any Progress In Diabetes On Safety?
No comments:
Post a Comment